Direct factor Xa inhibitor YM150 for prevention of stroke in subjects with non-valvular atrial fibrillation - a double blind, parallel, dose-finding study in comparison with open label warfarin.
Phase of Trial: Phase II
Latest Information Update: 16 Dec 2011
At a glance
- Drugs Darexaban; Warfarin
- Indications Embolism and thrombosis; Stroke
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 01 Sep 2010 Primary endpoint results presented at ESC Congress 2010: Annual Congress of the European Society of Cardiology
- 21 Jan 2009 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
- 21 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.